Jim Turpin

Title: Jim Turpin: Innovator in Antitumor Research

Introduction

Jim Turpin is a notable inventor based in Houston, TX (US). He has made significant contributions to the field of medical research, particularly in the development of antitumor factors. His innovative work has led to the creation of a unique patent that addresses critical challenges in cancer treatment.

Latest Patents

Jim Turpin holds a patent for a "Method for obtaining soluble antitumor factor." This patent discloses a novel antitumor factor, termed Human Monocyte Toxin (HMT), which is obtained through the precise activation of cells of monocyte/macrophage lineage. The process involves isolating monocytes in the absence of endotoxin by counterflow elutriation. The release of HMT can be triggered by exposure to low levels of various macrophage activating agents, leading to a rapid release that requires transcription, translation, and an intact secretory apparatus. The patent emphasizes the importance of precise control over the concentration of the triggering agent.

Career Highlights

Jim Turpin is affiliated with the University of Texas System, where he continues to advance his research in the field of oncology. His work has garnered attention for its potential impact on cancer therapies and treatment methodologies.

Collaborations

Throughout his career, Jim has collaborated with esteemed colleagues such as Gabriel Lopez-Berestein and Jim Klostergaard. These partnerships have further enriched his research and contributed to the advancement of antitumor studies.

Conclusion

Jim Turpin's innovative contributions to cancer research through his patent on Human Monocyte Toxin exemplify the critical role of inventors in the medical field. His work not only showcases his expertise but also holds promise for future advancements in cancer treatment.